RXST Share Price Performance
US$11.46
-23.59 (-67.30%)
14.1% undervalued intrinsic discount
US$13.35
Fair Value
Price US$11.46
AnalystHighTarget US$13.35
AnalystConsensusTarget US$9.89
Fair ValueUS$13.35
Share Pricen/a
RxSight, Inc. Stock Price
- 2 Narratives written by author
- 0 Comments on narratives written by author
- 15 Fair Values set on narratives written by author
RXST Community Narratives
AN
Fair Value US$13.35 14.1% undervalued intrinsic discount
Premium Cataract Adoption And International Expansion Will Drive Strong Long Term Potential
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value US$9.89 15.9% overvalued intrinsic discount
Entry Into European And Asian Markets Will Unlock New Opportunities
0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
Premium Cataract Adoption And International Expansion Will Drive Strong Long Term Potential
Catalysts About RxSight RxSight develops and commercializes the Light Adjustable Lens system to deliver personalized cataract surgery outcomes through postoperative adjustability. What are the underlying business or industry changes driving this perspective?Read more
4
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
US$13.35
14.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
4.27% p.a.
Profit Margin
12.91%
Future PE
34.53x
Price in 2028
US$16.68
Entry Into European And Asian Markets Will Unlock New Opportunities
Key Takeaways Strategic realignment and international expansion target higher adoption, utilization, and new revenue streams, leveraging demographic trends and a growing emphasis on vision correction. Investments in innovation, education, and clinical support aim to broaden market share, enhance margins, and build long-term pricing power within the premium IOL segment.Read more
54
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
11users have followed this narrative
AN
US$9.89
15.9% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
3.35% p.a.
Profit Margin
12.91%
Future PE
26.24x
Price in 2028
US$12.34
Trending Discussion
Recently Updated Narratives
AN
RXST: Future Returns Will Depend On Sustaining Recent Revenue Outperformance
Fair Value: US$9.89 15.9% overvalued intrinsic discount
11 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Premium Cataract Adoption And International Expansion Will Drive Strong Long Term Potential
Fair Value: US$13.35 14.1% undervalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
RxSight, Inc. Key Details
About RXST
- Founded
- 1997
- Employees
- 498
- CEO
- WebsiteView website
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be adjusted to improve uncorrected visual acuity; and RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
